Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.

Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, Peach RJ, Gujrathi S, Frohna PA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):263-276. doi: 10.1002/cpdd.383. Epub 2017 Aug 7.

2.

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA.

J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.

3.

Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis.

Dellon ES, Higgins LL, Beitia R, Rusin S, Woosley JT, Veerappan R, Selitsky SR, Parker JS, Genta RM, Lash RH, Aranda R, Peach RJ, Grimm M.

Aliment Pharmacol Ther. 2016 Jul;44(2):189-97. doi: 10.1111/apt.13672. Epub 2016 May 18.

4.

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.

Scott FL, Clemons B, Brooks J, Brahmachary E, Powell R, Dedman H, Desale HG, Timony GA, Martinborough E, Rosen H, Roberts E, Boehm MF, Peach RJ.

Br J Pharmacol. 2016 Jun;173(11):1778-92. doi: 10.1111/bph.13476. Epub 2016 Apr 28.

5.

Characterization of a subpopulation of colon cancer cells with stem cell-like properties.

Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, Nguyen ML, Hare E, Peach RJ.

Int J Cancer. 2009 Mar 15;124(6):1312-21. doi: 10.1002/ijc.24061.

6.

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ.

Am J Transplant. 2005 Mar;5(3):443-53.

7.
8.

CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung.

Harris NL, Prout M, Peach RJ, Fazekas de St Groth B, Ronchese F.

J Immunol. 2001 Apr 15;166(8):4908-14.

9.

Crystallization and preliminary X-ray analysis of CTLA-4 (CD152) membrane-external domain.

Chang CY, Fenderson WH, Lavoie TB, Peach RJ, Einspahr HM, Sheriff S.

Acta Crystallogr D Biol Crystallogr. 2000 Nov;56(Pt 11):1468-9.

PMID:
11053855
10.

Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection.

Lumsden JM, Roberts JM, Harris NL, Peach RJ, Ronchese F.

J Immunol. 2000 Jan 1;164(1):79-85.

12.

Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.

Metzler WJ, Bajorath J, Fenderson W, Shaw SY, Constantine KL, Naemura J, Leytze G, Peach RJ, Lavoie TB, Mueller L, Linsley PS.

Nat Struct Biol. 1997 Jul;4(7):527-31.

PMID:
9228944
13.

Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.

Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS.

J Biol Chem. 1995 Sep 8;270(36):21181-7.

14.

Endoproteolytic processing of recombinant proalbumin variants by the yeast Kex2 protease.

Ledgerwood EC, George PM, Peach RJ, Brennan SO.

Biochem J. 1995 May 15;308 ( Pt 1):321-5.

15.

Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.

Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naemura J, Linsley PS.

J Exp Med. 1994 Dec 1;180(6):2049-58.

16.

Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86).

Bajorath J, Peach RJ, Linsley PS.

Protein Sci. 1994 Nov;3(11):2148-50.

17.

Identification of hyaluronic acid binding sites in the extracellular domain of CD44.

Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A.

J Cell Biol. 1993 Jul;122(1):257-64.

19.

Albumin Rugby Park: a truncated albumin variant caused by a G-->C splice-site mutation in intron 13.

Peach RJ, Fellowes AP, Brennan SO, George PM.

Biochim Biophys Acta. 1992 Oct 13;1180(1):107-10.

PMID:
1390939
21.

Prediction of the site of signal peptidase cleavage in normal and variant human preproalbumin.

Peach RJ, Boswell DR, Brennan SO.

Protein Seq Data Anal. 1991 Aug;4(2):123-6.

PMID:
1946330
22.
23.

Rapid detection and initial characterization of genetic variants of human serum albumin.

Sheat JM, Peach RJ, George PM.

Clin Chem. 1991 Jul;37(7):1221-4.

25.
26.

Novel human proalbumin variant with intact dibasic sequence facilitates identification of its converting enzyme.

Brennan SO, Peach RJ, Boswell DR.

Biochim Biophys Acta. 1989 Oct 13;993(1):48-50.

PMID:
2679890
27.
28.

Characterisation of a slow component of normal human serum albumin.

Brennan SO, George PM, Peach RJ.

Clin Chim Acta. 1988 Aug 31;176(2):179-84.

PMID:
3180465
29.

Ultrastructural localization of Tamm-Horsfall protein in human kidney using immunogold electron microscopy.

Peach RJ, Day WA, Ellingsen PJ, McGiven AR.

Histochem J. 1988 Mar;20(3):156-64.

PMID:
3410739
30.
31.

A sensitive and specific ELISA using a monoclonal capture antibody for detection of Tamm-Horsfall urinary glycoprotein in serum.

Hunt JS, Peach RJ, Br├╝nisholz MC, Lynn KL, McGiven AR.

J Immunol Methods. 1986 Jul 11;91(1):35-43.

PMID:
3722831

Supplemental Content

Loading ...
Support Center